Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) has earned an average broker rating score of 1.13 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.

Brokers have set a 1 year consensus target price of $27.00 for the company, according to Zacks. Zacks has also given Clementia Pharmaceuticals an industry rank of 101 out of 265 based on the ratings given to related companies.

CMTA has been the topic of a number of recent research reports. BTIG Research started coverage on Clementia Pharmaceuticals in a research note on Thursday, August 31st. They set a “buy” rating and a $32.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $26.00 price target on shares of Clementia Pharmaceuticals in a research note on Tuesday, November 14th. Leerink Swann started coverage on Clementia Pharmaceuticals in a research note on Monday, August 28th. They issued an “outperform” rating and a $23.00 price target on the stock. Finally, Morgan Stanley started coverage on Clementia Pharmaceuticals in a research note on Monday, August 28th. They issued an “overweight” rating and a $27.00 price target on the stock.

Several institutional investors and hedge funds have recently modified their holdings of CMTA. Victory Capital Management Inc. bought a new position in shares of Clementia Pharmaceuticals in the 3rd quarter valued at $520,000. Birchview Capital LP bought a new position in shares of Clementia Pharmaceuticals in the 3rd quarter valued at $372,000. Sphera Funds Management LTD. bought a new position in shares of Clementia Pharmaceuticals in the 3rd quarter valued at $2,753,000. JPMorgan Chase & Co. bought a new position in shares of Clementia Pharmaceuticals in the 3rd quarter valued at $10,937,000. Finally, Citadel Advisors LLC bought a new position in shares of Clementia Pharmaceuticals in the 3rd quarter valued at $2,061,000. Institutional investors own 68.36% of the company’s stock.

Clementia Pharmaceuticals (CMTA) traded up $0.11 during trading on Monday, reaching $16.68. The company’s stock had a trading volume of 40,659 shares, compared to its average volume of 97,381. Clementia Pharmaceuticals has a 12-month low of $15.05 and a 12-month high of $18.95.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Set $27.00 Price Target for Clementia Pharmaceuticals Inc. (CMTA)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/zacks-brokerages-set-27-00-price-target-for-clementia-pharmaceuticals-inc-cmta/1764474.html.

About Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.